A new phase I clinical trial has demonstrated that belzutifan provides a route to sustained inhibition of hypoxia-inducible factor 2α in humans that is well tolerated and could be useful in the treatment of advanced clear cell kidney cancer.

中文翻译：

---

缺氧诱导因子 2 抑制剂在晚期肾癌中显示出希望

一项新的 I 期临床试验表明，belzutifan 提供了一种在人体中持续抑制缺氧诱导因子 2α 的途径，该途径具有良好的耐受性，可用于治疗晚期透明细胞肾癌。